# OnCo record pd-32766 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pd-32766/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pd-32766" ;
  schema:name "225Ac/64Cu-PD-32766 (CA9 theranostic pair)"@en ;
  schema:alternateName "PD-32766"@en, "225Ac-PD-32766"@en, "64Cu-PD-32766"@en, "PD-32766T"@en, "PD-32766D"@en ;
  schema:description "225Ac/64Cu-PD-32766 (CA9 theranostic pair) is an experimental radioligand peptide-drug conjugate, theranostic pair from PeptiDream, in phase 1 trials for clear cell renal cell carcinoma."@en ;
  schema:url <https://onco.cc/drugs/pd-32766/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.peptidream.com/en/pipeline/>, <https://www.peptidream.com/en/pipeline/>, <https://www.peptidream.com/en/pipeline/>, <https://clinicaltrials.gov/api/v2/studies/NCT07688187>, <https://clinicaltrials.gov/search?intr=PD-32766> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Radioligand peptide-drug conjugate (RI-PDC), theranostic pair" ;
  onco:cancers <https://onco.cc/cancers/clear-cell-rcc/> ;
  onco:companies <https://onco.cc/companies/peptidream/> ;
  onco:trials <https://onco.cc/trials/nct07688187/> .